Quininib, a CysLT1 antagonist, and its analogue, 1,4-dihydroxy quininib, are anti-inflammatory and anti-angiogenic drugs [32,33] with anti-cancer activity in human ex vivo colorectal cancer patient tumour explants and colorectal cancer xenograft models [34,35]. Here, CYSLTR1 is linked to neoplasm.